Showing results (91-100 of 141) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2019
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Valérie Lauwers-Cances, Elodie Tournay, et al.Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.Blood|February 16, 2022
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Xavier Leleu, Aurore Perrot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyélomeBruno Royer, Stéphane Minvielle, Momar Diouf, et al.Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.Pageof 15